ZA985277B - Novel ß-amino and ß-azido carboxylic and acid derivatives, their preparation and use as endothelin receptor antagonists. - Google Patents

Novel ß-amino and ß-azido carboxylic and acid derivatives, their preparation and use as endothelin receptor antagonists.

Info

Publication number
ZA985277B
ZA985277B ZA9805277A ZA985277A ZA985277B ZA 985277 B ZA985277 B ZA 985277B ZA 9805277 A ZA9805277 A ZA 9805277A ZA 985277 A ZA985277 A ZA 985277A ZA 985277 B ZA985277 B ZA 985277B
Authority
ZA
South Africa
Prior art keywords
amino
novel
preparation
acid derivatives
receptor antagonists
Prior art date
Application number
ZA9805277A
Inventor
Wilhelm Amberg
Andreas Kling
Dagmar Klinge
Hartmut Riechers
Stefan Hergenroeder
Manfred Raschack
Lilian Unger
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA985277B publication Critical patent/ZA985277B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9805277A 1997-06-19 1998-06-18 Novel ß-amino and ß-azido carboxylic and acid derivatives, their preparation and use as endothelin receptor antagonists. ZA985277B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19726146A DE19726146A1 (en) 1997-06-19 1997-06-19 New ß-amino and ß-azidopcarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
ZA985277B true ZA985277B (en) 1999-12-20

Family

ID=7833081

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9805277A ZA985277B (en) 1997-06-19 1998-06-18 Novel ß-amino and ß-azido carboxylic and acid derivatives, their preparation and use as endothelin receptor antagonists.

Country Status (22)

Country Link
EP (1) EP0994861A1 (en)
JP (1) JP2002504130A (en)
KR (1) KR20010013981A (en)
CN (1) CN1261352A (en)
AR (1) AR015893A1 (en)
AU (1) AU8213398A (en)
BG (1) BG104022A (en)
BR (1) BR9810182A (en)
CA (1) CA2294050A1 (en)
CO (1) CO4950605A1 (en)
DE (1) DE19726146A1 (en)
HR (1) HRP980331A2 (en)
HU (1) HUP0002714A3 (en)
ID (1) ID24346A (en)
IL (1) IL133104A0 (en)
NO (1) NO996268L (en)
NZ (1) NZ502319A (en)
PL (1) PL337507A1 (en)
SK (1) SK176299A3 (en)
TR (1) TR199903159T2 (en)
WO (1) WO1998058916A1 (en)
ZA (1) ZA985277B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19806438A1 (en) * 1998-02-17 1999-08-19 Basf Ag New pyrimidinyloxy-propionic acid derivatives useful as endothelin receptor antagonists in treatment of e.g. cardiac insufficiency, restenosis, hypertension, kidney failure, asthma and prostate cancer
DE19858779A1 (en) * 1998-12-18 2000-06-21 Basf Ag New 3-acylamino-propionic acid and 3-sulfonylamino-propionic acid derivatives useful as endothelin receptor antagonists in treatment of e.g. cardiovascular and renal disorders, migraine and cancer
DE19924892A1 (en) * 1999-06-01 2000-12-07 Basf Ag New carboxylic acid derivatives with aryl-substituted nitrogen heterocycles, their production and use as endothelin receptor antagonists
WO2002064573A1 (en) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Novel carboxylic acid derivatives containing alkyl substituted triazines, production of the same and use thereof as endothelin receptor antagonists
EP1632821B1 (en) 2004-09-01 2012-05-30 Océ-Technologies B.V. Intermediate transfer member with a cleaning member
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8217155B2 (en) 2007-07-31 2012-07-10 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
CN109422664B (en) * 2017-08-23 2022-02-18 中国科学院福建物质结构研究所 Interferon regulator and its prepn and use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
DE4411225A1 (en) * 1994-03-31 1995-10-05 Basf Ag Use of carboxylic acid derivatives as a drug
DE19614533A1 (en) * 1996-04-12 1997-10-16 Basf Ag New alpha-hydroxy acid derivatives, their production and use

Also Published As

Publication number Publication date
NO996268D0 (en) 1999-12-17
DE19726146A1 (en) 1998-12-24
NZ502319A (en) 2002-03-01
CN1261352A (en) 2000-07-26
JP2002504130A (en) 2002-02-05
ID24346A (en) 2000-07-13
EP0994861A1 (en) 2000-04-26
TR199903159T2 (en) 2000-07-21
NO996268L (en) 1999-12-17
BG104022A (en) 2001-04-30
HRP980331A2 (en) 1999-02-28
AU8213398A (en) 1999-01-04
SK176299A3 (en) 2000-06-12
WO1998058916A1 (en) 1998-12-30
AR015893A1 (en) 2001-05-30
CO4950605A1 (en) 2000-09-01
HUP0002714A2 (en) 2001-05-28
BR9810182A (en) 2000-08-08
CA2294050A1 (en) 1998-12-30
KR20010013981A (en) 2001-02-26
PL337507A1 (en) 2000-08-28
IL133104A0 (en) 2001-03-19
HUP0002714A3 (en) 2001-07-30

Similar Documents

Publication Publication Date Title
ZA9711316B (en) Vitronectin receptor antagonists, their preparation and their use.
ZA973143B (en) Substituted pyridines/pyrimidines, their preparation, and their use as pesticides.
HK1030939A1 (en) Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists
AU4552497A (en) Novel carboxylic acid derivatives, their preparation and use as mixed eta/etb receptor antagonists
HUP0002330A3 (en) Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists
AU4846497A (en) Vitronectin receptor antagonists, their preparation and their use
ZA200204814B (en) Substituted phenyl-piperazine derivatives, their preparation and use.
HUP0003484A3 (en) Pyrrolidine-3-crboxylic acid derivatives and their use as endothelin antagonists
ZA985277B (en) Novel ß-amino and ß-azido carboxylic and acid derivatives, their preparation and use as endothelin receptor antagonists.
IL135347A0 (en) New carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
PL351794A1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
ZA972794B (en) Substituted pyridines/pyrimidines, their preparation, and their use as pesticides.
AU5659498A (en) Heterocyclic carboxylic acid derivatives, their preparation ans use as endothelin receptor antagonists
NZ315846A (en) Endothelin receptor antagonists, in particular, substituted pyrazol-4-yl-substituted-prop-2-enoic acid derivatives
ZA979670B (en) Piperazino derivatives as neurokinin antagonists.
ZA9810425B (en) Novel heterocyclically substituted Ó-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists.
IL143451A0 (en) NEW- β-AMIDE AND β-SULFONAMIDE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
ZA967537B (en) Novel carboxylic acid derivatives, their preparation and use.
ZA991214B (en) Novel carboxylic acid derivatives having a 5-substituted pyrimidine ring, their preparation and use.
HK1049151A1 (en) Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists
ZA991738B (en) Novel unsymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed et /et receptor antagonists.
ZA988053B (en) Novel carboxylic acid derivatives, their preparation and use as mixed ETA/ETB receptor antagonists.
IL147666A0 (en) Novel carboxylic acid derivatives with 5, 6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists
ZA989923B (en) Novel carboxylic acid derivatives with amide side chains, their preparation and use as endothelin receptor antagonists.
IL146800A0 (en) Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their preparation and use as endothelin receptor antagonists